Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ImmuPharma boss excited by “blockbuster potential” of Lupuzor

The lupus treatment missed its primary endpoint in a phase III study earlier this year, but ImmuPharma CEO Tim McCarthy still has high hopes for the drug
scientist in lab
A blockbuster drug is one that generates peak annual sales of US$1bn or more

The chief executive of ImmuPharma PLC (LON:IMM) has told investors he is excited by the “blockbuster potential” of the company’s flagship lupus treatment, Lupuzor.

Earlier this month, ImmuPharma signed an agreement which will see it progress with a managed access programme, giving up to 500 lupus sufferers access to Lupuzor for a minimum of two years.

WATCH: ImmuPharma committed to Lupuzor ahead of managed access to programme

In addition to helping patients, the AIM-quoted drug developer expects to collect more valuable data on Lupuzor, which will be useful if and when it decides to press ahead with regulatory filings.

In April, the drug missed its primary endpoint in a late-stage study, but the outcome was more nuanced than the top line results suggested and actually showed that Lupuzor worked well in certain patients, chiefly those who were antibody-positive.

After the end of the phase III trial, 62 patients took part in a ‘follow-up’ study – called an open-label extension study. Results from this are expected in the second quarter of 2019.

Full regulatory approval

“It has been a busy period for the board following the announcement of the phase III trial results for Lupuzor in April 2018,” said chief executive Tim McCarthy.

“We were obviously disappointed with the outcome of the phase III trial results but are excited to be progressing the managed access programme with a new strategic partner, which allows lupus patients early access to Lupuzor.

“In the medium term, we remain focused on achieving the full regulatory approval of Lupuzor which we believe has the potential to be a ground-breaking drug for lupus patients with blockbuster potential in commercial terms.”

Nucant cancer programme making progress

Lupuzor isn’t ImmuPharma’s only drug going through the clinic. Its Nucant cancer treatment has yielded “promising results” in two phase I safety and dose-finding studies.

The company has signed heads of terms on a clinical development collaboration with oncology specialist Incanthera, in which ImmuPharma has taken a £2mln stake.

A licence agreement between the two is expected to be signed by the end of the year, a deal which is likely to see Incanthera pay an upfront licence fee of £1mln in shares and cover all of the development costs for the Nucant programme.

All future commercialisation revenues will be shared equally, ImmuPharma said.

Ureka to be divested

As for the firm’s Ureka subsidiary, which is looking to develop treatments for type II diabetes and NASH, the decision was recently made to sell it.

Despite having “exciting and innovative technologies”, the board does not see as part of the long-term strategy.

As a result, the plan is to divest the Bordeaux-based subsidiary whilst still retaining an interest should any of its drugs achieve some commercial success further down the line.

“Our Nucant programme and Ureka subsidiary have been part of our portfolio for a number of years.  We are equally excited by the potential of both,” said McCarthy.

“We believe the strategy we announced earlier this month, together with a robust financial position, will create enhanced value for shareholders going forward.”

Well-funded

Speaking of that “robust financial position”, thanks to a £10mln fundraise in January, ImmuPharma had £9.0mln of cash in the bank (H1 17: £2.7mln) at the end of June. Net assets grew to £9.9mln (H1 17: £3.6mln).

The company posted a loss for the six months to June 30 of £4.1mln, up from £3.0mln a year ago, reflecting a slight rise in R&D costs.

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

1530537220_Blood-Test.jpg
July 02 2018
The research and diagnostic company develops cancer-detecting blood tests
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
Lung X-Ray
October 08 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use